Inmune Bio, Inc. (INMB)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, Inmune Bio, Inc. reported revenue of $50.0K, up 257.1% from the prior year. The company ran a net loss, with a net margin of -91866.0%. It held $32.35M in total assets against $8.83M in total liabilities.
Key ratios (FY2025)
-94766.0%
Operating margin
-91866.0%
Net margin
-195.3%
Return on equity
+257.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | — | $0 | $0 | — |
| Operating Income | -$47.38M | -$42.63M | -$29.74M | -$25.95M | -$29.15M | -$12.23M | -$7.76M | -$12.44M | -$981.5K | — |
| Net Income | -$45.93M | -$42.08M | -$30.01M | -$27.30M | -$30.34M | -$12.10M | -$7.68M | -$12.44M | -$831.5K | — |
| EPS (Diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | — | — | — | — | — |
| Total Assets | $32.35M | $39.56M | $57.00M | $81.80M | $99.94M | $40.66M | $24.47M | $17.36M | $18.41M | — |
| Total Liabilities | $8.83M | $7.46M | $18.86M | $21.69M | $19.72M | $1.90M | $860.5K | $823.8K | $309.7K | — |
| Shareholders' Equity | $23.52M | $32.10M | $37.34M | $60.10M | $80.22M | $38.75M | $23.61M | $16.54M | $18.10M | -$149.2K |
| Cash & Equivalents | $24.75M | $20.92M | $35.85M | $52.15M | $74.81M | $21.97M | $7.00M | $186.2K | $1.37M | $141.7K |
| Operating Cash Flow | -$22.58M | -$33.36M | -$11.98M | -$22.69M | -$28.50M | -$8.94M | -$5.38M | -$2.06M | -$761.8K | — |
| Capital Expenditures | $1.04M | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | 26.59M | 22.28M | 17.95M | 17.95M | 17.84M | 13.48M | 10.77M | 8.72M | 8.32M | — |